Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03477903 · ClinicalTrials.gov registry record · Phase 2
TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI)
A Phase 2 study, sponsored by Millennium Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT03477903: Clinical Trial Phase 2 study, sponsored by Millennium Pharmaceuticals.
NCT03477903 is a Phase 2 study that was terminated before completion, run by Millennium Pharmaceuticals. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03477903, a Phase 2 study, was terminated before completion, sponsored by Millennium Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the treatment effect of intravenous TAK-954 in improving the average daily protein adequacy received through enteral nutrition in critically-ill participants developing EFI.
Primary Outcome
Average daily protein adequacy received through enteral nutrition is defined as the percentage of goal protein delivered per day, where percentage of goal protein delivered is calculated as the ratio of actual protein achievement to the total participant-specific target protein prescribed. The value for each of the 5 days was averaged.
Interventions
- DRUG Normal Saline
- DRUG Metoclopramide
- DRUG TAK-954
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2018-08-25 |
| Est. Completion | 2018-08-29 |
| Phase | Phase 2 |
Why NCT03477903 stopped before completion
NCT03477903 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 3 interventions - of which Normal Saline is the first listed.
NCT03477903 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03477903 about?
NCT03477903 is a clinical study titled "TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI)". The purpose of this study is to assess the treatment effect of intravenous TAK-954 in improving the average daily protein adequacy received through enteral nutrition in critically-ill participants developing EFI.
What is the current status of trial NCT03477903?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2018-08-25. Estimated completion is 2018-08-29.
What interventions are being tested in trial NCT03477903?
The interventions under investigation include: Normal Saline (DRUG), Metoclopramide (DRUG), TAK-954 (DRUG).
Who is sponsoring clinical trial NCT03477903?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03477903's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI